嵌合抗原受体
抗体疗法
抗体
医学
抗原
双特异性抗体
免疫疗法
受体
癌症研究
免疫学
细胞疗法
融合蛋白
细胞
遗传增强
靶向治疗
嵌合体(遗传学)
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-11-12
卷期号:: OF1-OF1
标识
DOI:10.1158/2159-8290.cd-nw2026-0106
摘要
Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.
科研通智能强力驱动
Strongly Powered by AbleSci AI